undamentalytics Newsletter
Sign in

Angiodynamics Inc (ANGO) stock

Add to watchlist

Add holding +

NASDAQ: ANGO Nasdaq Health Care Equipment Next results ~January 6, 2027

C+ Fundamentals grade

Angiodynamics Inc is a US-listed company in the health care equipment industry. Its financial year ends in May.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$8.9

Valuation models combined (3)

Base case. Range ~$6.3–$13. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Angiodynamics Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds86 adding, 70 cuttingOf 32 active managers that changed their stake, 15 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Angiodynamics files

Where Angiodynamics stands after its latest 10-Q

Revenue for the twelve months to August 2026 was $325m, up 8.2% on a year earlier, slower than the 9.5% growth a quarter earlier. Free-cash-flow margin rose to 0.4% from -4.0% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $13.61 a share, against a share price of $12.41.

Source: 10-Q filed October 8, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 6, 2027 (estimated)

Angiodynamics Inc's trailing-twelve-month revenue grew 8.2% year on year, with a free-cash-flow margin of 0.4%.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 65% in the quarter to 2026-08-31, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Loss-making. Operating margin is -11.2%: costs exceed revenue.
  • Volatile shares. Over the past year the shares showed annualised volatility of 48% and a beta of 1.0 against the S&P 500.

Latest results: FY2027 Q1

Filed October 8, 2026
Earnings per share
-$0.04 against an average estimate of -$0.11: beat by 64.7%
Revenue
$81m, up 6.9% on a year earlier
Share reaction
-18.8% in the first session after the results on October 8, 2026, against +0.2% for the S&P 500
Guidance given
net Sales $336m to $341m (fiscal year 2027); med Tech Net Sales Growth growth 12% to 15% (fiscal year 2027)
Next report
January 6, 2027; average EPS estimate -$0.07

Angiodynamics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.9%
  • 1 week-3.4%
  • 1 month-22.2%
  • This year-8.4%
  • 1 year-2.2%
  • 5 years-61.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$325M
Operating margin
-11.2%
Net margin
-10.1%
EPS (TTM, diluted)
$-0.79

Growth

Revenue growth
+8.2%
Change in growth rate
−1.3 pts
Share count change
+1.8%

Cash

Free cash flow (TTM)
$1.4M
FCF margin
0.4%
Stock pay % of revenue
4.3%

Earnings

Last results
October 8, 2026
Next results (est.)
January 5, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Guidance
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Angiodynamics Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Angiodynamics Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.79 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.3 ~$4.3–$7.5 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$10 ~$11–$39 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$13 ~$11–$17 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$8.9 ~$6.3–$13 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Angiodynamics Inc with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026Now
Share price$12.01$15.08$21.03$18.79$10.21$23.12$19.63$9.46$6.31$10.20$11.48$11.76
Market value$434m$552m$780m$704m$388m$886m$766m$373m$254m$417m$477m$491m
+ Net debt (− = net cash)−$16m$50m$18m−$95m−$54m−$48m−$4m$5m−$76m−$56m−$54m−$34m
Enterprise value$418m$602m$798m$609m$333m$838m$762m$379m$177m$361m$423m$457m
Multiples
Price / sales 1.2x2.0x3.0x2.6x1.5x3.0x2.4x1.1x0.8x1.4x1.5x1.5x
Price / earnings —110.3x47.7x11.5x————————
Price / free cash flow 10.1x10.5x20.0x20.5x—46.9x————n/mn/m
EV / EBITDA 14.4x44.2x88.7x37.0x——n/m—————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

53 /100

Moderate moat

How hard Angiodynamics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 8 / 20

    Cash operating profit has been a median 7.2% of total assets over 10 years.

  • Pricing power 18 / 20

    Gross margin has been a median 54.1%, moving by 2.3 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -10.9%; its worst year was -82.2%.

  • Cash conversion 5 / 20

    Free cash flow was positive in 5 of 10 years, at a median -0.5% of revenue.

  • Discipline 12 / 20

    The diluted share count rose 8.4% over five years; stock-based pay has been a median 3.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: January 6, 2027, before the open. Analysts expect revenue of $84m and EPS of −$0.07 (range −$0.11 to −$0.02) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.28 −87% $338m +6%
Next −$0.11 +60% $355m +5%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +5.7% on 90 days ago. In the last 30 days, 1 analyst raised Angiodynamics Inc's forecast and 0 cut it.

Consensus EPS forecast Angiodynamics Inc, last 90 days
−$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.27 Current fiscal year, 60 days ago: −$0.27 Current fiscal year, 30 days ago: −$0.27 Current fiscal year, 7 days ago: −$0.27 Current fiscal year, Now: −$0.28 −$0.28 Next fiscal year, 90 days ago: −$0.04 Next fiscal year, 60 days ago: −$0.04 Next fiscal year, 30 days ago: −$0.04 Next fiscal year, 7 days ago: −$0.04 Next fiscal year, Now: −$0.11 −$0.11

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.27−$0.04
60 days ago −$0.27−$0.04
30 days ago −$0.27−$0.04
7 days ago −$0.27−$0.04
Now −$0.28−$0.11

Earnings against estimates

Quarter toEstimateActualSurprise
Aug 2026 −$0.11 −$0.04 +64.7%
May 2026 −$0.09 −$0.07 +22.2%
Feb 2026 −$0.11 $0.02 +118.2%
Nov 2025 −$0.10 $0.00 +100.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 8, 2026
  • Net Sales fiscal year 2027 $336m to $341m Maintained
    “Net Sales $336.0M - $341.0M” source
  • Adjusted EPS fiscal year 2027 $-0.29 to $-0.24 Non-GAAP Maintained
    “Adjusted EPS ($0.29) - ($0.24)” source
  • Gross Margin fiscal year 2027 54% to 55% Maintained
    “Gross Margin 54% - 55%” source
  • Med Tech Net Sales Growth fiscal year 2027 12% growth to 15% growth Maintained
    “Med Tech Net Sales Growth 12% - 15%” source
  • Adjusted EBITDA fiscal year 2027 $13m to $16m Non-GAAP Maintained
    “Adjusted EBITDA $13.0M - $16.0M” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202644

Counts of recommendations published by analysts covering Angiodynamics Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.9%
of tradable shares
Days to cover
2.02
at average volume
Short interest, 1 month
+43%
to October 15, 2026
Held by institutions
93%
of shares
Held by insiders
13.1%
of shares
Employees
632
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −2.2%

$12.03 on October 31, 2025 to $11.76

ThenNowEffect
Revenue (last 12 months) $301m $325m +8.2%
P/S multiple 1.6x 1.5x −8.0%
Share count 41m 42m −1.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +72.7%

$6.81 on November 3, 2023 to $11.76

ThenNowEffect
Revenue (last 12 months) $336m $325m −3.1%
P/S multiple 0.8x 1.5x +87.7%
Share count 40m 42m −5.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ANGO+80%−50%−43%+17%+40%−8%
Industry peers (median)−9%−37%−8%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ANGO67%25%33%50%67%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ANGO−21%−59%−60%−34%−35%−32%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 83% from November 5, 2021 to March 25, 2024. Getting back needed a 488% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$9.70 – $16.13
From 52-week high
−27.1%
vs 50-day average
−16.6%
vs 200-day average
−5.8%
Volatility (1 year)
48%
Beta vs S&P 500
1.04

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±16.2%
After a week
5 up, 7 down
typical move ±16.2%
After a month
5 up, 6 down
typical move ±13.6%
Results releasedNext dayS&P 500 next day5 days21 days
October 8, 2026 −18.8% +0.2% −18.4% —
July 14, 2026 +13.2% +0.8% +11.3% +23.2%
April 2, 2026 −17.6% +0.6% −17.9% −8.0%
January 6, 2026 −17.5% +0.3% −23.9% −24.0%
October 2, 2025 +5.1% +0.1% +0.6% +8.7%
July 15, 2025 −10.7% −0.1% −5.2% −5.9%
April 2, 2025 +1.7% −4.3% −1.1% −3.8%
January 8, 2025 +30.9% −1.4% +35.9% +15.4%
October 3, 2024 −20.3% +0.7% −19.7% −12.7%
July 16, 2024 +24.8% −0.8% +26.1% +20.9%
April 4, 2024 +15.6% −0.2% +11.8% +3.1%
January 5, 2024 −17.7% +1.6% −22.6% −23.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Angiodynamics Inc in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Angiodynamics Inc
$280M $300M $320M $340M FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $329.5M Revenue (TTM), FY24 Q3: $324M Revenue (TTM), FY24 Q4: $303.9M Revenue (TTM), FY25 Q1: $292.7M Revenue (TTM), FY25 Q2: $286.5M Revenue (TTM), FY25 Q3: $283.3M Revenue (TTM), FY25 Q4: $292.5M Revenue (TTM), FY26 Q1: $300.7M Revenue (TTM), FY26 Q2: $307.3M Revenue (TTM), FY26 Q3: $313.7M Revenue (TTM), FY26 Q4: $320.2M Revenue (TTM), FY27 Q1: $325.4M $325.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $329.5M
FY24 Q3 $324M
FY24 Q4 $303.9M
FY25 Q1 $292.7M
FY25 Q2 $286.5M
FY25 Q3 $283.3M
FY25 Q4 $292.5M
FY26 Q1 $300.7M
FY26 Q2 $307.3M
FY26 Q3 $313.7M
FY26 Q4 $320.2M
FY27 Q1 $325.4M
Revenue growth, TTM YoY Angiodynamics Inc
-20% -10% 0% 10% 20% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: 0.5% Revenue growth, TTM YoY, FY24 Q3: -3.2% Revenue growth, TTM YoY, FY24 Q4: -10.3% Revenue growth, TTM YoY, FY25 Q1: -12.9% Revenue growth, TTM YoY, FY25 Q2: -13.1% Revenue growth, TTM YoY, FY25 Q3: -12.6% Revenue growth, TTM YoY, FY25 Q4: -3.8% Revenue growth, TTM YoY, FY26 Q1: 2.7% Revenue growth, TTM YoY, FY26 Q2: 7.3% Revenue growth, TTM YoY, FY26 Q3: 10.7% Revenue growth, TTM YoY, FY26 Q4: 9.5% Revenue growth, TTM YoY, FY27 Q1: 8.2% 8.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 0.5%
FY24 Q3 -3.2%
FY24 Q4 -10.3%
FY25 Q1 -12.9%
FY25 Q2 -13.1%
FY25 Q3 -12.6%
FY25 Q4 -3.8%
FY26 Q1 2.7%
FY26 Q2 7.3%
FY26 Q3 10.7%
FY26 Q4 9.5%
FY27 Q1 8.2%
Operating margin (TTM) Angiodynamics Inc
-100% -50% 0% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: -2.4% Operating margin (TTM), FY24 Q3: -61.4% Operating margin (TTM), FY24 Q4: -63.3% Operating margin (TTM), FY25 Q1: -82.2% Operating margin (TTM), FY25 Q2: -83.3% Operating margin (TTM), FY25 Q3: -17.2% Operating margin (TTM), FY25 Q4: -13.7% Operating margin (TTM), FY26 Q1: -12.5% Operating margin (TTM), FY26 Q2: -10.6% Operating margin (TTM), FY26 Q3: -11.3% Operating margin (TTM), FY26 Q4: -12.5% Operating margin (TTM), FY27 Q1: -11.2% -11.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -2.4%
FY24 Q3 -61.4%
FY24 Q4 -63.3%
FY25 Q1 -82.2%
FY25 Q2 -83.3%
FY25 Q3 -17.2%
FY25 Q4 -13.7%
FY26 Q1 -12.5%
FY26 Q2 -10.6%
FY26 Q3 -11.3%
FY26 Q4 -12.5%
FY27 Q1 -11.2%
FCF margin (TTM) Angiodynamics Inc
-15% -10% -5% 0% 5% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY24 Q2: -1.9% FCF margin (TTM), FY24 Q3: -6.2% FCF margin (TTM), FY24 Q4: -10.1% FCF margin (TTM), FY25 Q1: -8.0% FCF margin (TTM), FY25 Q2: -9.2% FCF margin (TTM), FY25 Q3: -10.0% FCF margin (TTM), FY25 Q4: -5.0% FCF margin (TTM), FY26 Q1: -4.0% FCF margin (TTM), FY26 Q2: -3.0% FCF margin (TTM), FY26 Q3: 0.5% FCF margin (TTM), FY26 Q4: 0.2% FCF margin (TTM), FY27 Q1: 0.4% 0.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -1.9%
FY24 Q3 -6.2%
FY24 Q4 -10.1%
FY25 Q1 -8.0%
FY25 Q2 -9.2%
FY25 Q3 -10.0%
FY25 Q4 -5.0%
FY26 Q1 -4.0%
FY26 Q2 -3.0%
FY26 Q3 0.5%
FY26 Q4 0.2%
FY27 Q1 0.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 May 2010 2011 May 2011 2012 May 2012 2013 May 2013 2014 May 2014 2015 May 2015 2016 May 2016 2017 May 2017 2018 May 2018 2019 May 2019 2020 May 2020 2021 May 2021 2022 May 2022 2023 May 2023 2024 May 2024 2025 May 2025 2026 May 2026 LTM Aug 2026
Income
Revenue 216 216 222 342 354 357 354 270 262 271 264 291 316 339 304 292 320 325
Gross profit 127 126 125 169 180 176 174 144 144 156 150 157 166 174 155 158 175 181
EBITDA 33 24 9 32 39 26 29 14 9 16 −143 −9 1 −20 −165 −14 −17 −14
Operating income 21 12 −5 5 10 −3 1 −11 −14 −9 −167 −35 −28 −51 −192 −40 −40 −37
Net income 12 8 −5 −1 2 −3 −44 5 16 61 −167 −32 −27 −52 −184 −34 −37 −33
Diluted EPS $0.50 $0.32 −$0.20 −$0.03 $0.07 −$0.09 −$1.21 $0.14 $0.44 $1.64 −$4.39 −$0.82 −$0.68 −$1.33 −$4.59 −$0.83 −$0.88 −$0.79
Growth (year on year)
Revenue — −0.2% +2.9% +54.1% +3.7% +0.6% −0.7% −23.8% −3.0% +3.4% −2.4% +10.2% +8.7% +7.1% −10.3% −3.8% +9.5% +8.2%
EBITDA — −26.6% −61.5% +244.2% +19.5% −32.0% +10.3% −53.2% −34.0% +83.3% −969.3% — — — — — — —
Operating income — −43.0% −144.1% — — −132.9% — — — — — — — — — — — —
Net income — −34.4% −166.0% — — — — — — +275.5% −371.9% — — — — — — —
Diluted EPS — −36.0% −162.5% — — — — — — +272.7% −367.7% — — — — — — —
Margins
Gross margin 58.8% 58.2% 56.5% 49.3% 50.8% 49.3% 49.3% 53.4% 55.0% 57.6% 56.9% 53.9% 52.4% 51.4% 50.9% 53.9% 54.6% 55.7%
EBITDA margin 15.4% 11.4% 4.3% 9.5% 11.0% 7.4% 8.2% 5.1% 3.4% 6.1% −54.2% −3.2% 0.3% −6.0% −54.2% −4.8% −5.3% −4.3%
Operating margin 9.7% 5.5% −2.4% 1.5% 3.0% −1.0% 0.3% −4.1% −5.4% −3.5% −63.3% −12.1% −9.0% −15.1% −63.3% −13.7% −12.5% −11.2%
Net margin 5.7% 3.7% −2.4% −0.3% 0.7% −1.0% −12.3% 1.9% 6.2% 22.7% −63.1% −10.8% −8.4% −15.5% −60.7% −11.6% −11.5% −10.1%
Free-cash-flow margin 16.2% 14.3% 4.1% 4.3% 3.8% 4.0% 12.1% 19.6% 14.9% 12.7% −8.2% 6.5% −3.6% −1.1% −10.1% −5.0% 0.2% 0.4%
Cash flow
Cash from operations 40 34 12 27 25 26 45 56 41 37 −15 24 −7 0 −28 −10 3 4
Capital spending 5 3 2 12 11 11 2 3 2 3 7 5 4 4 3 4 3 2
Free cash flow 35 31 9 15 14 14 43 53 39 34 −22 19 −11 −4 −31 −15 1 1
Stock-based pay 5 5 4 5 6 6 3 6 8 9 8 9 11 11 11 10 14 14
Free cash flow after stock pay 30 26 5 10 8 8 40 47 31 25 −29 10 −22 −15 −41 −24 −13 −13
Balance sheet
Cash 59 46 24 16 18 18 32 48 74 228 54 48 29 45 76 56 54 34
Total debt 0 7 150 143 143 70 16 98 93 133 — 0 25 50 0 0 0 0
Net debt (negative = net cash) −59 −39 126 126 124 52 −16 50 18 −95 −54 −48 −4 5 −76 −56 −54 −34
Diluted shares 25m 25m 25m 35m 35m 36m 36m 37m 37m 37m 38m 38m 39m 39m 40m 41m 42m 42m
Returned to shareholders
Dividends — — 0 0 0 — — — — — — — — — — — — —
Buybacks — — 2 0 0 0 0 14 0 0 — — — 0 0 2 0 —
Total returned — — 2 0 0 0 0 14 0 0 — — — 0 0 2 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · August 31, 2026
What it owns · $242m
Short-term assets $143mLonger-term assets $99m
What it owes, and who funded it · $242m
Short-term liabilities $60mLonger-term liabilities $18mShareholders' equity $164m
  • Short-term assets cover short-term liabilities $143m of assets due within a year against $60m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $143m short-term assets against $18m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Angiodynamics Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q4 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Buybacks, last 3 fiscal years
$1.7M
Diluted share count
+1.8%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
R&D spending
9.5%
of revenue
Days sales outstanding
50 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated ANGO PRCT STAA INGN TCMD SKIN Median
Revenue, last 12 months $325m $337m $340m $354m $356m $290m $99m
Revenue growth, last 12 months 8.2% 22.7% 51.3% 3.2% 14.4% −6.5% 9.2%
Revenue growth, 3-year average −1.1% 49.2% 9.2% 0.5% 9.6% −9.5% 13.5%
Revenue growth, latest quarter 6.9% 19.3% 111.0% 3.0% 7.1% −7.8% 10.2%
Gross margin 55.7% 64.2% 76.6% 44.5% 77.0% 66.4% 61.2%
Operating margin −11.2% −33.9% 4.0% −8.7% 9.4% −1.5% −8.5%
Operating margin, 3-year average −35.3% −43.1% −12.3% −16.2% 8.1% −17.9% −17.9%
Net margin −10.1% −32.5% 1.1% −6.9% 6.7% −9.8% −12.0%
Cash from operations / revenue 1.1% −22.0% −1.0% −0.7% 9.0% 7.6% −1.9%
Free-cash-flow margin 0.4% −25.2% −2.0% −1.4% 8.1% 7.3% −3.9%
Free-cash-flow margin, 3-year average −3.8% −39.8% −5.8% −1.8% 11.6% 6.8% −7.0%
Stock pay / revenue 4.3% 15.7% 8.3% 2.1% 2.5% 3.8% 6.1%
Change in share count 1.8% 4.2% 2.6% 8.9% −1.7% −1.8% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 8.2% 9.1% 72 of 129
Change in growth rate Growth -1.3pp -0.6pp 80 of 129
Gross margin Profitability 55.7% 61.9% 76 of 123
Operating margin Profitability -11.2% -8.3% 71 of 132
Net margin Profitability -10.1% -12.0% 61 of 133
Free-cash-flow margin Cash generation 0.4% -3.4% 51 of 128
Stock pay as % of revenue Cash generation 4.3% 6.1% 54 of 123
Change in share count Balance sheet 1.8% 3.3% 45 of 115
Days sales outstanding Balance sheet 50 days 57 days 43 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to May 31, 2026
Segments
Line of business Revenue Share YoY
Med Device $170M 53.2% ▲ 2.6%
Med Tech $150M 46.8% ▲ 18.4%
Products and services
Line of business Revenue Share YoY
Med Device $170M 53.2% ▲ 2.6%
Med Tech $150M 46.8% ▲ 18.4%
Geography
Region Revenue Share YoY
United States $275M 85.9% ▲ 9.5%
Outside the US $45.3M 14.1% ▲ 9.0%

From Angiodynamics Inc's 10-K filed July 14, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$497M
Institutions reporting
162
Shares held vs prior quarter
▼ 1.0%
Positions opened / closed
30 / 14

Top buyers and sellers, Q2 2026: 86 institutions bought and 70 sold ; the biggest buyer was Royce & Associates LP (+441K shares) and the biggest seller Divisadero Street Capital Management, LP (−562K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $49.5M 3.8M 10.0% ▲ 3.2%
Point72 Asset Management, L.P. $39.8M 3.1M 8.0% ▼ 3.7%
Systematic Financial Management LP $34.3M 2.6M 6.9% ▲ 7.6%
Armistice Capital, LLC $28.6M 2.2M 5.8% ▲ 17.6%
Royce & Associates LP $25.6M 2.0M 5.2% ▲ 28.8%
Broadfin Holdings LLC $23.7M 1.8M 4.8% ▼ 12.1%
Vanguard Capital Management LLC $22M 1.7M 4.4% ▼ 1.9%
Weber Capital Management LLC $17.6M 1.4M 3.6% ▼ 1.2%
Nuveen, LLC $15.6M 1.2M 3.1% ▼ 1.4%
Geode Capital Management, LLC $13.3M 1.0M 2.7% ▲ 3.6%
Dimensional Fund Advisors LP $12.6M 969K 2.5% ▲ 2.2%
State Street Corp $12.5M 958K 2.5% ▼ 28.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Angiodynamics Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $654,695 3 trades by 2 insiders · 0% under pre-set plans
Net ▼ $654,695 net selling
Insider Date Trade Shares Price Value
Trowbridge Stephen A EVP and CFO October 29, 2026 Sell 23,615 $12.27 $289,756
Trowbridge Stephen A EVP and CFO October 28, 2026 Sell 1,720 $12.17 $20,932
Nighan Warren Jr SVP Quality and Regulatory July 30, 2026 Sell 23,370 $14.72 $344,006

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 6 trades and filings

No trades in Angiodynamics Inc disclosed in the last 12 months; 6 earlier trades on record.

  • Debbie Wasserman Schultz(D-FL 25):Sale (full), $2,000.00, traded October 20, 2025, filed October 24, 2025
  • Debbie Wasserman Schultz(D-FL 25):Sale (full), $1,001 - $15,000, traded July 16, 2025, filed July 25, 2025
  • Debbie Wasserman Schultz(D-FL 25):Purchase, $1,001 - $15,000, traded June 27, 2025, filed July 25, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 5, 2027 estimated from the company's past filing pattern, not announced

  • October 8, 2026
  • July 14, 2026
  • April 2, 2026
  • January 6, 2026
  • October 2, 2025
  • July 15, 2025

Recent SEC filings

Data status

When each part of this page on Angiodynamics Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Angiodynamics Inc in brief

What does Angiodynamics Inc do?
Angiodynamics Inc is a US-listed company in the health care equipment industry. Its financial year ends in May.
What is Angiodynamics Inc's stock ticker?
Angiodynamics Inc trades under the ticker ANGO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Angiodynamics Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Angiodynamics Inc reported revenue of $325M, 8.2% higher than a year earlier, according to its SEC filings.
What is Angiodynamics Inc's free cash flow?
Angiodynamics Inc's free-cash-flow margin is 0.4% of revenue over the trailing twelve months, ranking 51 of the 128 health care equipment companies we cover.
Who are Angiodynamics Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Point72 Asset Management, L.P. and Systematic Financial Management LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Angiodynamics Inc buying back stock, and does it pay a dividend?
Angiodynamics Inc spent $0 on share repurchases over the trailing twelve months, and its diluted share count still rose 1.8% over the year.
What is Angiodynamics Inc's market cap?
On November 2, 2026, Angiodynamics Inc's market capitalisation was about $491M and net debt of -$34M. Market figures come from third-party market data and may be delayed.
Who are Angiodynamics Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Angiodynamics Inc are Procept Biorobotics Corp, Staar Surgical Co, Inogen Inc, Tactile Systems Technology Inc and Skinhealth Systems Inc. The side-by-side comparison below sets their revenue, margins and growth against Angiodynamics Inc's.
Are insiders buying or selling Angiodynamics Inc stock?
Over the last 12 months, Angiodynamics Inc's directors and officers reported 0 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
When is Angiodynamics Inc's next earnings date?
Around January 6, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Angiodynamics Inc announces its own schedule.